Filing Flows › Mereo BioPharma Group (MREO) › Q2 2025
Mereo BioPharma Group (MREO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Mereo BioPharma Group (MREO) reported revenue of $500K for the second quarter 2025 (Q2 2025).
Revenue$500K
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$14.6M
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $500K | — | — |
| Operating profit | −$10.5M | — | — |
| Net earnings | −$14.6M | — | — |
| Operating cash flow | −$7.7M | — | — |
What changed
Revenue was $500K in Q2 2025.
Operating costs exceeded revenue by $10.5M, an operating margin of -2099.8%. The quarter ended with a net loss of $14.6M.
Operating cash flow was −$7.7M. Non-cash charges added back $162K of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items added $4.7M.
Questions
What was Mereo BioPharma Group's revenue in the second quarter 2025?
Mereo BioPharma Group (MREO) reported revenue of $500K for the second quarter 2025 (Q2 2025).